uniQure is a Dutch biopharmaceutical company specializing in gene therapies built on an adeno-associated virus (AAV) technology platform. With more than two decades of experience in gene therapy and genomic medicine, the company has established a track record of industry firsts. These include developing Glybera, the first gene therapy approved in the Western world (European Union approval in 2012), and the world's first FDA-approved gene therapy for hemophilia B, which received approval in 2022.
The company's technical domains span gene therapy, AAV technology, genomic medicine, and manufacturing. Its operations are headquartered in the Netherlands with a global reach. uniQure's work is concentrated in the biopharmaceutical, gene therapy, and genomic medicine sectors, positioning it as a pioneer in applying gene therapy to serious medical conditions.
